Shopping Cart
- Remove All
Your shopping cart is currently empty
ZLDI-8 is an inhibitor of Notch activating/cleaving enzyme ADAM-17 and inhibits the cleavage of Notch protein.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $52 | Backorder | |
| 5 mg | $123 | Backorder | |
| 10 mg | $198 | Backorder | |
| 25 mg | $372 | Backorder | |
| 50 mg | $596 | Backorder | |
| 100 mg | $953 | Backorder | |
| 1 mL x 10 mM (in DMSO) | $135 | Backorder |
| Description | ZLDI-8 is an inhibitor of Notch activating/cleaving enzyme ADAM-17 and inhibits the cleavage of Notch protein. |
| Targets&IC50 | ADAM17:31.6 μM , Tyrosine phosphatase:, Tyrosine phosphatase:(ki)26.22 μM |
| In vitro | ZLDI-8;?it inhibited the cleavage of NOTCH protein, consequently decreased the expression of pro-survival/anti-apoptosis and EMT related proteins.?ZLDI-8 treatment enhanced the susceptibility of HCC cells to a small molecular kinase inhibitor Sorafenib, and chemotherapy agents Etoposide and Paclitaxel.?ZLDI-8 treatment enhanced the effect of Sorafenib on inhibiting tumor growth in nude HCC-bearing mice model[1]. |
| In vivo | In nude HCC-bearing mice model, ZLDI-8 (0.2-2 mg/kg; intraperitoneal injection; every two days; for 20 days; nude mice) treatment enhances the effect of Sorafenib on inhibiting tumor growth [1]. |
| Molecular Weight | 433.52 |
| Formula | C24H23N3O3S |
| Cas No. | 667880-38-8 |
| Smiles | Cc1c(C=C2C(=O)NC(=S)NC2=O)c2ccccc2n1CCOc1ccc(C)cc1C |
| Relative Density. | 1.30 g/cm3 (Predicted) |
| Color | White |
| Appearance | solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 62.5 mg/mL (144.17 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.